<i>gyrA</i> Mutations in <i>Mycoplasma genitalium</i> and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy

Abstract

Compared with parC S83I SNP alone, M. genitalium infections with dual mutations affecting parC/gyrA had twice the likelihood of failing moxifloxacin. Although antimicrobial resistance varies by region globally, these data indicate that gyrA should be considered as a target for future resistance assays in Australasia. We propose a strategy for the next generation of resistance-guided therapy incorporating parC and gyrA testing.